Europe · Markets & Finance · Option Finance

Eli Lilly dévoile des résultats positifs de phase 3b pour Ebglyss

Published by Option Finance · France 18 h ago

Le groupe pharmaceutique Eli Lilly a présenté les données clés d'une étude de phase 3b évaluant Ebglyss (lebrikizumab-lbkz) en monothérapie qui a atteint l'ensemble de ses…

Read the full article on Option Finance Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.optionfinance.fr)

Also worth reading

City A.M.

Bring ‘punishing’ high street taxes in line with banks, Healey urged

Financial Times

Trump says South Korea will invest $200bn in US energy projects

This is Money

Bailey's fears AI could trigger next crash should not be sneezed at, says ALEX BRUMMER

FXStreet

The New Zealand Dollar edges lower as US yields outweigh China's beats

Reuters Markets

Fed's Kashkari says central bank must lower inflation pressures

Reuters Sustainability